睿知中国疾病研究地图
候选清单0

正在招募多发性骨髓瘤早期I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases

ClinicalTrials.gov 上登记的一项多发性骨髓瘤开放试验,由浙江大学医学院附属第一医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)浙江大学医学院附属第一医院First Affiliated Hospital, Zhejiang University杭州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT04662294,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. Histologically confirmed diagnosis of CD70 AML per the US National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Acute Myeloid Leukemia (2016.v1);

    入选标准第 1 条

    Histologically confirmed diagnosis of DLBCL (NOS), FL, DLBCL transformed from CLL/SLL, PMBCL, and HGBCL per the WHO Classification Criteria for Lymphoma (2016);

    入选标准第 15 条

    Histologically confirmed diagnosis of CD70 multiple myeloma (MM):

    入选标准第 21 条

  2. ECOG performance status 0 to 2;

    入选标准第 12 条

    ECOG performance status 0 to 2;

    入选标准第 30 条

    ECOG performance status 0 to 2;

    入选标准第 36 条

  3. Total bilirubin ≤ 51 umol/L, ALT and AST ≤ 3 times of upper limit ofnormal, creatinine ≤ 176.8 umol/L;

    入选标准第 8 条

    Total bilirubin ≤ 51 umol/L, ALT and AST ≤ 3 times of upper limit of normal, creatinine ≤ 176.8 umol/L;

    入选标准第 26 条

    Total bilirubin ≤ 51 umol/L, ALT and AST ≤ 3 times of upper limit of normal, creatinine ≤ 176.8 umol/L;

    入选标准第 32 条

    Creatinine >2.5mg/dl, or ALT / AST>3 times of normal amounts, or bilirubin>2.0 mg/dl;

    排除标准第 8 条

  4. Patients with HIV infection;

    排除标准第 10 条

  5. Pregnant (or lactating) women;

    排除标准第 3 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);既往治疗;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT04662294,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Histologically confirmed diagnosis of CD70 AML per the US National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Acute Myeloid Leukemia (2016.v1);
  2. Relapsed or refractory CD70+ AML (meeting one of the following conditions):
  3. CR not achieved after standardized chemotherapy;
  4. CR achieved following the first induction, but CR duration is less than 12 months;
  5. Ineffectively after first or multiple remedial treatments;
  6. 2 or more relapses;
  7. The number of primordial cells in bone marrow is > 5% (by morphology), and/or > 0.01% (by flowcytometry);
  8. Total bilirubin ≤ 51 umol/L, ALT and AST ≤ 3 times of upper limit ofnormal, creatinine ≤ 176.8 umol/L;
  9. Echocardiogram shows left ventricular ejection fraction (LVEF) ≥50%;
  10. No active infection in the lungs, blood oxygen saturation in indoorair is ≥ 92%;
  11. Estimated survival time ≥ 3 months;
  12. ECOG performance status 0 to 2;
  13. Patients or their legal guardians volunteer to participate in the studyand sign the informed consent.
  14. No gender and age limit;
  15. Histologically confirmed diagnosis of DLBCL (NOS), FL, DLBCL transformed from CLL/SLL, PMBCL, and HGBCL per the WHO Classification Criteria for Lymphoma (2016);
  16. Relapsed or refractory CD70+ NHL (meeting one of the following conditions):
  17. No response or relapse after second-line or above chemotherapy regimens;
  18. Primary drug resistance;
  19. Relapse after auto-HSCT;
  20. At least one assessable tumor lesion per Lugano 2014 criteria
  21. Histologically confirmed diagnosis of CD70 multiple myeloma (MM):
  22. According to the diagnostic criteria of IMWG multiple myeloma, the diagnosis was recurrent / refractory multiple myeloma
  23. Cases with recurrent positive minimal residual disease;
  24. Extramedullary leision which is hard to be eradicated by chemotherapy or radiotherapy.
  25. No gender and age limit;
  26. Total bilirubin ≤ 51 umol/L, ALT and AST ≤ 3 times of upper limit of normal, creatinine ≤ 176.8 umol/L;
  27. Echocardiogram shows left ventricular ejection fraction (LVEF) ≥50%;
  28. No active infection in the lungs, blood oxygen saturation in indoorair is ≥ 92%;
  29. Estimated survival time ≥ 3 months;
  30. ECOG performance status 0 to 2;
  31. Patients or their legal guardians volunteer to participate in the studyand sign the informed consent.
  32. Total bilirubin ≤ 51 umol/L, ALT and AST ≤ 3 times of upper limit of normal, creatinine ≤ 176.8 umol/L;
  33. Echocardiogram shows left ventricular ejection fraction (LVEF) ≥ 50%;
  34. No active infection in the lungs, blood oxygen saturation in indoor air is ≥ 92%;
  35. Estimated survival time ≥ 3 months;
  36. ECOG performance status 0 to 2;
  37. Patients or their legal guardians volunteer to participate in the study and sign the informed consent -

排除标准:Exclusion Criteria:

  1. History of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular hemorrhagic diseases;
  2. Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past;
  3. Pregnant (or lactating) women;
  4. Patients with severe active infections (excluding simple urinary tract infection and bacterial pharyngitis);
  5. Active infection of hepatitis B virus or hepatitis C virus;
  6. Concurrent therapy with systemic steroids within 2 weeks prior to screening, except for the patients recently or currently receiving inhaled steroids;
  7. Previously treated with any CAR-T cell product or other geneticallymodified T cell therapies;
  8. Creatinine >2.5mg/dl, or ALT / AST>3 times of normal amounts, or bilirubin>2.0 mg/dl;
  9. Other uncontrolled diseases that were not suitable for this trial;
  10. Patients with HIV infection;
  11. Any situations that the investigator believes may increase the risk of patients or interfere with the results of study. -

引自 ClinicalTrials.gov, NCT04662294, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT04662294,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT04662294